Results 241 to 250 of about 1,093,324 (351)

Innovation and the role of the cardiac morphologist [PDF]

, 2009
Aiello, VD, Anderson, RH, Jacobs, JP, Spicer, DE, Yoo, SJ   +4 more
core   +1 more source

Systemic embolization after aortic valve replacement

, 1967
Robert S. Fraser, J. Aubrey Waddell
openalex   +1 more source

Aortic valve-specific genes dysregulated in calcific aortic valve stenosis as potential biomarkers and therapeutic targets. [PDF]

HGG Adv
Zamani P, Houessou U, Manikpurage HD, Li Z, Dahmene M, Gaudreault N, Dagenais F, Clavel MA, Pibarot P, Arsenault BJ, Mathieu P, Bossé Y, Thériault S.   +12 more
europepmc   +1 more source

Obstruction of the aorta by prosthetic aortic valve

, 1968
Frank W. Quattlebaum, B.R. Kalke, Jesse E. Edwards, C. Walton Lillehei   +3 more
openalex   +1 more source

Alternative Transaxillary Access for Transcatheter Aortic Valve Implantation. [PDF]

J Clin Med
Wisniewski K, Kaleschke G, De-Torres-Alba F, Martens S, Deschka H.   +4 more
europepmc   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Clinical impact of tricuspid regurgitation in patients with acute myocardial infarction

ESC Heart Failure, EarlyView.
Abstract Aims The clinical impact of tricuspid regurgitation (TR) in patients after acute myocardial infarction (AMI) is largely unknown. The aim of this study was to clarify the prevalence and prognostic impact of TR in post‐AMI patients treated with appropriate primary percutaneous coronary intervention (PCI).
Shun Nishino, Chiharu Nishino, Michikazu Nakai, Kensaku Nishihira, Nehiro Kuriyama, Yoshisato Shibata   +5 more
wiley   +1 more source

Aortic homograft valve replacement of the mitral valve

, 1967
W.G. Bigelow, A.S. Trimble, Pierre Auger, E.Douglas Wigle   +3 more
openalex   +1 more source

Rationale and design of the randomized ‘early ventricular assist device’—Trial (VAD‐DZHK3)

ESC Heart Failure, EarlyView.
The VAD‐DZHK3 trial is a randomised controlled study evaluating whether elective LVAD implantation improves outcomes in end‐stage heart failure (HF) patients listed for heart transplantation compared with delayed implantation after clinical deterioration.
Christoph Knosalla, Gloria Färber, Andreas J. Rieth, Rolf Wachter, Marius Placzek, Wolfgang Albert, Gerd Hasenfuß, Volkmar Falk, Tim Friede, for the VAD‐DZHK3 Investigators   +9 more
wiley   +1 more source